Foghorn Therapeutics, Inc. (FHTX) News
Filter FHTX News Items
FHTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FHTX News Highlights
- FHTX's 30 day story count now stands at 2.
- Over the past 15 days, the trend for FHTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest FHTX News From Around the Web
Below are the latest news stories about FOGHORN THERAPEUTICS INC that investors may wish to consider to help them evaluate FHTX as an investment opportunity.
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's WhyFoghorn Therapeutics Inc. (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%The average of price targets set by Wall Street analysts indicates a potential upside of 160.6% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual MeetingCAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the Phase 1 dose escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held |
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Price Is Right But Growth Is Lacking After Shares Rocket 27%Those holding Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shares would be relieved that the share price has rebounded 27... |
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsFlagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo |
News Flash: Analysts Just Made A Sizeable Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) ForecastsFoghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders will have a reason to smile today, with the analysts making... |
Foghorn Therapeutics Inc (FHTX) Reports Q3 2023 Financial Results and Corporate UpdatesCompany's cash position extends runway into 2026, with significant progress in clinical trials and collaborations |
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate UpdateFirst patient dosed in FHD-286 combination study in AML; data expected in the second half of 2024Transitioned the BRM Selective inhibitor program to Loxo@LillyPresented preclinical data demonstrating tumor growth inhibition and favorable safety profiles for Selective EP300 and Selective CBP programsCash, cash equivalents, and marketable securities of $259.9 million, as of September 30, 2023, provides cash runway into the first half of 2026 CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Fogh |
Flagship Pioneering Launches Pioneering IntelligenceFlagship Pioneering today launched Pioneering Intelligence, an initiative of Flagship Pioneering harnessing artificial intelligence (AI) to accelerate innovation in the life sciences and beyond. Flagship marked the official launch of Pioneering Intelligence with an AI Summit that drew tech and life sciences leaders from around the globe for a day long series of talks. Initiated in 2021, Pioneering Intelligence will augment the capabilities of Flagship companies, drive AI and machine learning (ML |
We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |